Earnings call transcript: Implantica Q4 2024 sees mixed financial results
Implantica reported a mixed financial performance for Q4 2024, with a 30% year-over-year decrease in quarterly revenue to €442,000, while full-year net sales rose by 38% to €1.9 million. The company's ...
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
JD Supra1d
2025 Perspectives in Private Equity: International Trade Regulations & Tariffs
If there is one thing that we can be sure of as the new administration settles into the White House, it is that there will be a heightened focus ...
Al Bawaba News2d
Aramex Delivers Double-Digit Topline Performance for FY 2024, Driven by Consistent Volume Growth Across Key Products
Aramex (DFM: ARMX) a leading global provider of comprehensive logistics and transportation solutions, today announced its ...
How Are Active Equity Managers Positioning Portfolios For Increased U.S. Import Tariffs?
U.S. import tariff policy remains highly fluid, with announcements of new levies against imports from Canada, Mexico, and ...